Rubicon Analysis Restricted is arising with its Preliminary Public Providing (IPO) that opens on October 9, 2025, and closes on October 13, 2025. The problem contains each a contemporary difficulty of ₹500 crores and a suggestion on the market of ₹877.50 crores, aggregating as much as ₹1,377.50 crores. Allow us to do an in depth Rubicon Analysis IPO Overview, protecting its difficulty particulars, dates, financials, strengths, dangers, GMP, and valuation evaluation, and discover out whether or not you need to make investments or keep away from this IPO.
About Rubicon Analysis Restricted
Rubicon Analysis Restricted, included in 1999, is a pharmaceutical firm engaged within the growth, manufacturing, and commercialization of differentiated formulations. The corporate’s portfolio consists of 72 accepted ANDA/NDA merchandise by the US FDA, out of which 66 merchandise are commercialized. Rubicon additionally has 17 new merchandise underneath US FDA approval and 63 underneath growth.
As of June 2025, Rubicon caters to over 96 clients throughout 350+ SKUs, together with main US wholesalers and GPOs. It operates three manufacturing services in India and two US FDA-approved R&D facilities in India and Canada.
The corporate has additionally expanded its presence to worldwide markets together with the UK, Australia, Singapore, Saudi Arabia, and UAE.
Aggressive Strengths
- Quickest-growing Indian pharmaceutical participant amongst friends.
- Sturdy R&D basis with sturdy data-driven formulation growth.
- Deep US market penetration – provides to main wholesalers and pharmacies.
- USFDA-approved services making certain robust compliance.
- Confirmed observe document of profitability and progress.
- Skilled management staff with technical and enterprise acumen.
Rubicon Analysis IPO Situation Particulars
| Particulars | Particulars |
|---|---|
| IPO Opening Date | October 9, 2025 |
| IPO Closing Date | October 13, 2025 |
| IPO Dimension | ₹1,377.50 Crores |
| Contemporary Situation | ₹500 Crores |
| Supply for Sale (OFS) | ₹877.50 Crores |
| Value Band | ₹461 – ₹485 per share |
| Face Worth | ₹1 per share |
| Lot Dimension | 30 Shares |
| Minimal Funding (Retail) | ₹14,550 |
| Itemizing Trade | BSE, NSE |
| E book Working Lead Managers | Axis Capital, JM Monetary, IIFL Capital, SBI Capital Markets |
| Registrar | MUFG Intime India Pvt. Ltd. |
Firm Financials (Restated Consolidated)
| Particulars (in ₹ Cr) | FY23 | FY24 | FY25 | Q1 FY26* |
|---|---|---|---|---|
| Whole Earnings | 419 | 872 | 1,296 | 357 |
| PAT | -16.9 | 91.0 | 134.4 | 43.3 |
| EBITDA | 43.9 | 173.1 | 267.9 | 79.7 |
| Internet Price | 286 | 385 | 541 | 594 |
| Debt/Fairness Ratio | 0.73 | 0.73 | 0.73 | – |
| PAT Margin | -4.0% | 10.4% | 10.4% | 12.1% |
*As of June 30, 2025.
Key Metrics:
- ROE: 29.02%
- ROCE: 26.45%
- EBITDA Margin: 20.67%
Objects of the Situation
The online proceeds from the contemporary difficulty might be utilized for:
- Prepayment/compensation of sure excellent borrowings – ₹3,100 million.
- Funding inorganic progress and strategic acquisitions.
- Common company functions.
Valuation – P/E Ratio vs Friends
| Firm | CMP (₹) | EPS (₹) | P/E | Remarks |
|---|---|---|---|---|
| Rubicon Analysis Ltd (at higher value) | 485 | 8.7 | 55.7x | Reasonable |
| Solar Pharma | – | 43.2 | 35x | Established large-cap |
| Cipla | – | 42.1 | 33x | Sturdy home model |
| Torrent Pharma | – | 58.7 | 45x | Excessive-margin participant |
| Business Common | 38x |
👉 Rubicon’s P/E of ~55x appears on the upper facet in comparison with the trade common, reflecting the corporate’s excessive progress expectation however comparatively premium valuation.
Causes to Put money into Rubicon Analysis IPO
- Quickly increasing US generics footprint and diversified world presence.
- Excessive margin and return ratios (ROE > 29%) point out environment friendly capital use.
- Sturdy R&D pipeline with a number of merchandise awaiting USFDA approval.
- Rising income and income during the last three years.
- Debt discount by means of IPO proceeds can enhance profitability.
- Distinguished institutional backing (Common Atlantic Singapore) provides credibility.
Threat Components within the IPO
- Excessive dependence on US markets (90%+ revenues) – regulatory dangers.
- Premium valuation in comparison with trade friends.
- International trade fluctuations can impression margins.
- Pending USFDA approvals can delay product launches.
- Extremely aggressive pharma sector with pricing pressures.
- Debt ranges nonetheless reasonably excessive submit compensation.
Rubicon Analysis IPO GMP (Gray Market Premium)
As of October 5, 2025, the Rubicon Analysis IPO GMP is round ₹40-45 per share, indicating an inventory acquire of ~8-10% over the higher value band. Nevertheless, GMPs are likely to fluctuate till itemizing.
Find out how to Apply for Rubicon Analysis IPO
You may apply for the Rubicon Analysis IPO by means of any of the next:
- ASBA facility – by way of your financial institution’s internet banking portal (Axis, HDFC, SBI, ICICI, and many others.)
- UPI-based functions by means of Zerodha, Groww, Upstox, Angel One, and many others.
- Bodily ASBA varieties – obtainable at financial institution branches.
Conclusion – Ought to You Put money into Rubicon Analysis IPO?
Rubicon Analysis is a high-growth pharma firm with robust fundamentals, sturdy R&D capabilities, and increasing world attain. The corporate’s monetary efficiency has been spectacular, with constant progress in income and margins.
Nevertheless, the valuation (P/E ~55x) seems costly in comparison with friends, and the excessive dependence on the US market provides focus danger.
✅ My View: Reasonable-risk buyers with a long-term horizon could contemplate subscribing for itemizing beneficial properties and long-term progress, whereas conservative buyers could look forward to higher valuations post-listing.
Steadily Requested Questions (FAQs)
1. What’s Rubicon Analysis IPO date?
Rubicon Analysis IPO opens on October 9, 2025, and closes on October 13, 2025.
2. What’s the Rubicon Analysis IPO value band?
The IPO value band is ₹461 to ₹485 per share.
3. What’s the Rubicon Analysis IPO dimension?
The overall difficulty dimension is ₹1,377.50 crores.
4. How a lot is the minimal funding for retail buyers?
Retail buyers can apply with a minimal of 1 lot (30 shares) value ₹14,550.
5. What’s the Rubicon Analysis IPO GMP in the present day?
As of now, the Gray Market Premium (GMP) is round ₹40-45.
6. Who’re the promoters of Rubicon Analysis?
Promoters embrace Common Atlantic Singapore RR Pte. Ltd., Pratibha Pilgaonkar, and Sudhir Pilgaonkar.
7. Must you put money into Rubicon Analysis IPO?
Traders with medium-to-high danger urge for food can contemplate for itemizing beneficial properties and long-term potential.
IPO Disclaimer
Investing in IPOs entails market dangers. Please learn the Pink Herring Prospectus (RHP) rigorously and seek the advice of your monetary advisor earlier than investing. The data on myinvestmentideas.com is for instructional functions solely and never funding recommendation.
